South Finance Intelligence News, November 21st: Hengrui Medicine (01276.HK) announced that the company and its subsidiaries, Suzhou Shendiab Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., and Shanghai Shendi Pharmaceutical Co., Ltd., have recently received the approval notices for clinical trials issued by the National Medical Products Administration for Injection SHR-9839(sc), Injection SHR-A2009, Injection SHR-1826, HRS-4642 Injection, Adabeleli Monoclonal Antibody Injection, Injection Rui Kang Trastuzumab, Injection SHR-A2102, HRS-7058 Capsule and HRS-7058 Tablets. These drugs have been approved for clinical trials. Among them, SHR-9839 is a humanized antibody drug independently developed by the company, intended for the treatment of advanced solid tumors, with a cumulative R&D investment of approximately 72.31 million yuan; Injection SHR-A2009 is an antibody-drug conjugate targeting HER3, and there are no similar drugs approved for market worldwide, with a cumulative R&D investment of approximately 227 million yuan; Injection SHR-1826 is an antibody-drug conjugate targeting c-MET, with a cumulative R&D investment of approximately 101 million yuan; HRS-4642 Injection is a KRASG12D inhibitor, with a cumulative R&D investment of approximately 191 million yuan; Adabeleli Monoclonal Antibody Injection has been approved for the first-line treatment of extensive-stage small cell lung cancer, with global sales of similar products totaling approximately 9.648 billion US dollars in 2024, and a cumulative R&D investment of approximately 969 million yuan; Injection Rui Kang Trastuzumab has been approved for domestic market in May 2025 for the treatment of HER2-mutated non-small cell lung cancer, with global sales of similar products totaling approximately 6.557 billion US dollars in 2024, and a cumulative R&D investment of approximately 1.415 billion yuan; Injection SHR-A2102 is an antibody-drug conjugate targeting Nectin-4, with global sales of similar products totaling approximately 194.9 million US dollars in 2024, and a cumulative R&D investment of approximately 248 million yuan; HRS-7058 is a KRASG12C inhibitor, with global sales of similar products totaling approximately 485 million US dollars in 2024, and a cumulative formulation R&D investment of approximately 69.57 million yuan. The company reminds that there are uncertainties in the process from clinical trials to market launch of drugs, and the company will continue to advance research and development and fulfill its information disclosure obligations.

https://finance.eastmoney.com/a/202511213571566942.html